Splitting Ironwood
Why splitting in two could finally give Ironwood and investors their just rewards
Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates to treat a range of serious, underserved diseases.
But unlike other biotechs that have reached this inflection point, its stock hasn’t been well-rewarded for either its commercial success or its R&D. ...